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Background: Infection by Plasmodium vivax has been considered rarely threatening to life, but recent studies
challenge this notion. This study documented the frequency and character of severe illness in paediatric patients
admitted to a hospital in south-eastern Pakistan with a laboratory-confirmed diagnosis of vivax malaria.
Methods: An observational study of all 180 paediatric patients admitted with any diagnosis of malaria during 2010
was conducted: 128 P. vivax; 48 Plasmodium falciparum; and four mixed infections of these species. Patients were
classified as having severe illness with any of the following indicators: Glascow coma scale <11; ≥2 convulsions;
haemoglobin <5g/dL; thrombocytes <50,000/mL; blood glucose <45mg%; >70 breaths/min; or intravenous anti-
malarial therapy. Additionally, 64 patients with a diagnosis of vivax malaria were treated during 2009, and the 21 of
these having severe illness were included in analyses of the frequency and character of severe illness with that
diagnosis.
Results: During 2010, 39 (31%) or 37 (77%) patients with a diagnosis of P. vivax or P. falciparum were classified as
having severe disease. Including the 2009 records of 64 patients having vivax malaria, a total of 60 (31%) patients
with severe illness and a diagnosis of P. vivax were available. Altered mental status (Glascow coma scale score <11;
or ≥2 convulsions) dominated at 54% of the 83 indicators of severe illness manifest among the patients with vivax
malaria, as was true among the 37 children with a diagnosis of falciparum malaria and being severely ill; 58% of the
72 indicators of severe disease documented among them. No statistically significant difference appeared in
frequencies of any other severe disease indicators between patients diagnosed with vivax or falciparum malaria.
Despite such similarities, a diagnosis of falciparum malaria nonetheless came with 3.8-fold (95% CI = 1.8-8.1) higher
risk of presenting with severe illness, and 8.0-fold (95% CI = 2.1-31) greater likelihood of presenting with three or
more severe disease indicators. Two patients did not survive hospitalization, one each with a diagnosis of
falciparum or vivax malaria.
Conclusions: Vivax malaria caused a substantial burden of potentially life-threatening morbidity on a paediatric
ward in a hospital in south-eastern Pakistan.
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In Russell’s 1949 text of malariology [1], S.F. Kitchen wrote,
“As a general rule vivax infections exhibit relatively benign
characteristics. . .instances of death (of otherwise healthy
adults) due to this parasite alone must indeed be rare.”
This remained the prevailing view of malariologists over
the ensuing decades. Only recently has evidence emerged
suggesting that, on the contrary, life-threatening illness
with a diagnosis of vivax malaria may often be encountered
in many endemic settings [2-6]. Kitchen’s experience with
this infection, limited largely to adults in non-endemic set-
tings undergoing therapy for neurosyphilis, likely explains
the careful qualification of his expressed view. Endemic
settings may create circumstances that exacerbate vivax
malaria, and paediatric populations may be particularly
likely to encounter those as yet unknown determinants.
With almost three billion people living at risk of vivax mal-
aria and at least 100 million clinical attacks annually [7,8],
the frequency, character, and risks of life-threatening illness
associated with a diagnosis of Plasmodium vivax repre-
sents a conspicuously important global health issue.
Endemic falciparum and vivax malaria occur in Paki-
stan [9]. At a hospital in south-eastern Pakistan very ill
children with a microscopic diagnosis of P. vivax have
long been noted [10]. Perhaps like other practitioners in
resource-limited settings, other undiagnosed causes of
severe illness were often presumed: misdiagnosed or
cryptic falciparum malaria, or any number of bacterial
or viral agents beyond diagnostic reach in poorly
resourced laboratories. However, as reports emerged of
severe illness associated with vivax malaria, in 2009 an
effort was undertaken to systematically collect clinical
and laboratory information from patients referred to
paediatric ward with a diagnosis of malaria. These stud-
ies aimed to characterize the frequency and character of
severe disease with a diagnosis of vivax malaria relative
to a diagnosis of Plasmodium falciparum in the same
population.
Methods
Liaquat University Hospital (LUH), affiliated with Lia-
quat University of Medical and Health Sciences, is a
1,600-bed private teaching hospital in Hyderabad, Sindh
Province, Pakistan. The LUH is the primary referral hos-
pital for the city of Hyderabad and surrounding rural
communities. In 2009 the hospital admitted 2,956 adult
patients (at least 17 years of age) and 6,395 paediatric
patients. Malaria accounted for 433 (15%) and 148
(2.3%) of adult and paediatric admissions, respectively.
Most adults had falciparum malaria (72%), whereas chil-
dren had approximately equal shares of falciparum
(57%) and vivax (43%) malaria.
Two paediatric patient populations composed distinct
analytical approaches to the studies undertaken: 1) aretrospective case series of 21 patients diagnosed with
P. vivax mono-infection and classified as having severe
illness (collected from June to October 2009 from
among the 64 with vivax malaria evaluated during that
period); and 2) observational study of the records of 176
patients diagnosed with either P. falciparum or P. vivax
mono-infections and treated in the paediatric depart-
ment (April to December 2010). All data were gleaned
from records of routine patient care. A protocol describ-
ing these studies was reviewed and approved by the eth-
ics review board of Liaquat University of Medical and
Health Sciences.
During July and August 2009, blood films from 12
patients diagnosed as having severe illness and P. vivax,
along with 10 others diagnosed as having severe illness
and P. falciparum, were evaluated by expert microscopists
and by standard nested PCR [11] at the US Naval Medical
Research Unit #2 (NAMRU-2) in Jakarta, Indonesia. Blood
films from an additional nine patients with a diagnosis of
P. vivax (July to October 2009) were evaluated by expert
microscopy at the Eijkman-Oxford Clinical Research Unit
in Indonesia. Two certified (by US NAMRU-2 [12]) expert
malaria microscopists blindly read blood films from all 39
patients admitted to the paediatric department with a
diagnosis of vivax malaria and having severe illness (April
to December 2010).
Patients were classified as having severe disease on the
basis of objective clinical or laboratory features as follows:
Glascow coma scale (GCS) <11; ≥2 episodes of convul-
sions; haemoglobin level <5 g/dL; respiratory rate >70
breaths/min; thrombocytes <50,000/mL; blood glucose
level <45mg%; or the administration of anti-malarials
intravenously. Patients exhibiting none of these features
were classified as having uncomplicated malaria. Except-
ing intravenous antimalarial therapy, these criteria were
extracted from the WHO criteria for classifying patients
with a diagnosis of falciparum malaria as having severe,
complicated, and life-threatening disease [13]. We applied
these criteria equally to patients with either falciparum or
vivax malaria in order to compare frequencies of these
syndromes between species of infection. No studies have
validated the syndromes or associated values as risk fac-
tors for poor outcomes with vivax malaria. In the instance
of intravenous therapy, we applied this physician’s judge-
ment outcome as at least incompatible with a classifica-
tion of uncomplicated illness.
Results and discussion
During 2009 the paediatric ward admitted 64 children
with a diagnosis of vivax malaria (Figure 1). Additional
file 1:Table S1 lists clinical and laboratory findings in 21
(33%) of those patients classified as having severe illness.
The diagnosis of P. vivax was confirmed by PCR in 12 of
these children, and review by two expert microscopists
Figure 2 Distribution of syndromes among patients having at
least one qualifying clinical or laboratory feature consistent
with a classification of severe malaria with Plasmodium vivax
(black bars; 83 syndromes among 60 patients) or Plasmodium
falciparum (grey bars; 72 syndromes among 37 patients).
Comparisons between frequencies for vivax and falciparum malaria
within syndromes showed no significant differences (P= 0.171-0.806).
Figure 1 Classification of patients with a diagnosis of malaria treated at the paediatrics ward at Liaquat University Hospital in 2009
and 2010.
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two convulsions (57%) and five had GCS <11 (24%),
three of those patients having both. Eight patients (38%)
had severe anaemia (<5g/dL), with two of those also hav-
ing both ≥2 convulsions and GCS< 11. None of the
patients exhibited respiratory distress (although most
had well above normal respiration rates for their age
groups), only one of 12 evaluated had severe thrombo-
cytopaenia (<50,000/mL), another had hypoglycaemia
(22mg%), and just one showed a bleed time >8min. All
of these children recovered after treatment by either
chloroquine syrup or quinine infusion.
Figure 1 illustrates the classification of the 178 patients
seen in the paediatric department with a microscopically
confirmed diagnosis of falciparum or vivax malaria during
2010. Four other patients had a diagnosis of malaria
caused by both P. falciparum and P. vivax; these patients
were excluded from subsequent statistical analyses. Blood
films from all of the 39 patients classified as having vivax
malaria and severe illness yielded the same diagnosis from
the two blinded reads by expert microscopists in Indo-
nesia. Vivax malaria accounted for 71% of malaria cases
evaluated, 51% of admissions for malaria, and 51% of cases
classified as severely ill. Additional file 2: Table S2 lists
clinical and laboratory findings among the 39 patients
having at least one severe disease syndrome and a con-
firmed diagnosis of P. vivax. Among the 13 of these mana-
ged as outpatients, 12 had severe thrombocytopaenia only,
and the other had severe anaemia alone as consistent with
the classification as severely ill. Three inpatients also had
only severe thrombocytopaenia, but, in contrast to the
relatively brief bleed times of those managed as outpati-
ents, they all bled in excess of nine minutes. That observa-
tion prompted admission to hospital.Figure 2 illustrates the distribution of 72 and 83 severe
disease syndromes among 37 (2010 only) and 60 (2009
and 2010) patients with falciparum or vivax malaria, re-
spectively. Among comparisons of the distribution fre-
quencies of syndromes between P. vivax- and P.
falciparum-infected patients, no statistically significant
differences emerged (P = 0.171-0.802). GCS< 11 and ≥2
convulsions dominated among severe disease syndromes.
The proportion of patients classified with either or both
of these syndromes was not significantly higher with a
diagnosis of P. falciparum vs P. vivax (OR= 1.7; 95%-
CI = 0.6-4.7).
Figure 3 illustrates the distribution of the number of
severe disease syndromes per patient between those
diagnosed with P. vivax or P. falciparum. Vivax malaria
Figure 3 Relative frequencies of multiple-severe disease
syndromes among patients with a diagnosis of Plasmodium
vivax (black bars; n = 60) or Plasmodium falciparum. (grey bars;
n = 37). An asterisk to the right of the bars indicates statistically
significant difference. All other comparisons were not significant
(P =0.177-0.883).
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falciparum malaria (69% vs 22%; P< 0.001). Likewise, a
diagnosis of P. falciparum more often came with three
or more severe disease syndromes than with P. vivax
(21% vs 3%; P< 0.001). Expressed differently, a diagnosis
of falciparum malaria was 3.8 times (95%CI = 1.8-8.1)
more likely to be classified as severe (≥1 syndrome), and
8.0 times (95%CI = 2.1-31) more likely to involve more
than two indicators of severe illness.
Two deaths attributed to malaria occurred during the
study period, one with a diagnosis of P. falciparum and
one with P. vivax. The death with falciparum malaria oc-
curred in a three month-old female admitted with GCS
of 6, convulsive, respiratory distress (70b/min), and se-
vere thrombocytopaenia (39,000/mL). She died three
days after admission. Death with diagnosis of vivax mal-
aria occurred in a 12 year-old girl admitted with GCS of
10, convulsive, and hypoglycaemic (34mg%). She died
seven days after admission.
Other studies in the South Asia region report somewhat
similar findings in hospitalized paediatric populations.
Among 103 children hospitalized with a diagnosis of vivax
malaria at Bikaner, India, 65 (63%) were classified as having
severe disease [14]. A similarly high rate of severe illness
among the hospitalized in this study occurred: 30/39 (77%).
While the Bikaner study found high rates of multi-organ
system involvement in vivax malaria (69%), only 19 of the
60 (32%) patients with severe vivax malaria in the current
hospital of study in 2009 and 2010 had involvement of
more than one organ system. For falciparum malaria in
this hospital, 60% of severely ill patients had involvement
of more than one severe disease syndrome, much likethe 62% rate at Bikaner. Cerebral syndromes in patients
with vivax malaria in the current study appeared to be
more common, with coma and convulsions accounting
for 48% of severely ill patients, compared to just 14% at
Bikaner [14]. Severe anaemia appeared among severely ill
children with vivax malaria in the current study hospital
(18%), but not nearly as frequently as at Bikaner (75%)
[14]. Nonetheless, lesser grades of anaemia were certainly
a significant problem in the patient population (47% of
severely ill with <9g/dL; see Additional files 1: Table S1
and Table S2). Other studies in India [15-18] describe
patients having severe vivax malaria characterized by
cerebral syndromes, severe thrombocytopaenia, severe an-
aemia and shock syndromes. Large studies from Indonesia
documented severe anaemia, altered mental status, and
pulmonary distress among children and adults with a
diagnosis of vivax malaria [19,20].
The observational studies described in this report have
important limitations. A number of other endemic infec-
tions may have affected the patients in this study, but
the laboratory capacities required to systemically assess
these were lacking. Underlying disease, malnutrition for
example, may represent important determinants of exa-
cerbated vivax malaria but none were systematically
assessed in these studies. Nonetheless, almost all of the
patients in these studies recovered with anti-malarial
therapies (few received presumptive antibiotics) and as-
sociation between the confirmed diagnosis and clinical
disease may be considered at least probable. Further
prospective studies in endemic zones like south-eastern
Pakistan supported by wider arrays of diagnostics for
infections and other disease states are needed.
The means of classifying severe illness in this study
represents another limitation with these studies. The
standard WHO thresholds for disease severity derive
from thorough statistical assessments of clinical and la-
boratory indicators associated with risk of fatal outcome
with a diagnosis of falciparum malaria [13]. No such
assessments have been carried out with vivax malaria
and the current study simply applied those syndromes
and thresholds without similar evidence of statistical
linkage to a poor prognosis. This approach, uniform
disease classification between infecting species, permit-
ted comparison of rates of disease states. The occurrence
of coma and convulsions in patients with vivax malaria
may be through cellular and molecular processes dis-
similar to those thought to occur in falciparum malaria,
i.e., by adhesion of infected red blood cells in deep
microvasculature. Red cells infected by P. vivax show lit-
tle propensity for such adhesion [21]. Nonetheless, by
any direct or indirect mechanism of onset, and regard-
less of associated risk of death, coma and convulsions
may not be reconciled with a classification of uncompli-
cated illness. The patients with a diagnosis of vivax
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ing at least potentially threatening disease states.
Conclusions
Although a diagnosis of malaria caused by P. falciparum
carried significantly higher risks of more often severe and
more complicated illness, a diagnosis of vivax malaria
nonetheless accounted for 51% of the burden of severe ill-
ness attributed to malaria. The range and frequency of
syndromes – dominated by altered mental status, severe
thrombocytopaenia, and severe anaemia – were indistin-
guishable between patients with either diagnosis. The
expressed caveat of Kitchen on the improbability of threa-
tening disease with vivax malaria, i.e., “. . .(in otherwise
healthy adults). . .”, may prove historically important as
better understanding of vivax malaria as it occurs in en-
demic zones emerges, especially in children. Although
relative risks varied between falciparum and vivax malaria,
both of these diagnoses came with the same range of po-
tentially life-threatening syndromes at very substantial
rates with respect to overall burdens. A diagnosis of infec-
tion by P. vivax, regardless of what co-factors or determi-
nants may come into play, often came with clinically
threatening conditions in the patients evaluated in this
study. The long-held view of vivax malaria as a benign in-
fection may threaten patients by inviting inappropriately
casual attention to its clinical management, research, and
control. The commitment of just 3.1% of global funding
for malaria research to P. vivax between 2007 and 2009
[22] suggest that such may be the case.
Additional files
Additional file 1: Table S1. Case series summary of 21 patients
classified as having severe disease with a diagnosis of vivax malaria
during 2009.
Additional file 2: Table S2. Case series summary of 39 patients
classified as having severe disease with a diagnosis of vivax malaria
during 2010.
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